We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+59.12%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$8.26B
AUM Growth
+$2.81B
Cap. Flow
+$660M
Cap. Flow %
7.99%
Top 10 Hldgs %
46.78%
Holding
97
New
16
Increased
23
Reduced
35
Closed
10
Avg Time Held
1.3 years
Top 10 Avg Time Held
1.5 years
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$242M
2
STTK icon
Shattuck Labs
STTK
+$181M
3
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$164M
4
ABBV icon
AbbVie
ABBV
+$133M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$91.4M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$275M
2
BNTX icon
BioNTech
BNTX
+$64.3M
3
BSX icon
Boston Scientific
BSX
+$54.3M
4
FOLD icon
Amicus Therapeutics
FOLD
+$50.2M
5
AXNX icon
Axonics, Inc. Common Stock
AXNX
+$37.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Technology 0.52%
3 Financials 0.46%
4 Consumer Staples 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GWPH
26
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$94.1M 1.14%
+815,681
New +$91.4M
2020 Q4
0 quarters
NRIX icon
27
Nurix Therapeutics
NRIX
$2.73B
$93.6M 1.13%
2,846,125
+252,555
+10% +$8.37M
2020 Q3
1 quarter
AVIR icon
28
Atea Pharmaceuticals
AVIR
$363M
$93.2M 1.13%
+2,231,710
New +$71.9M
2020 Q4
0 quarters
RPTX icon
29
DELISTED
Repare Therapeutics
RPTX
$90.8M 1.1%
2,647,696
+242,722
+10% +$7.25M
2020 Q2
2 quarters
KLRS icon
30
Kalaris Therapeutics
KLRS
$52.1M
$89.4M 1.08%
101,113
-339
-0.3% -$261K
2020 Q3
1 quarter
TCRR
31
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$87.6M 1.06%
2,832,888
+39,600
+1% +$1M
2019 Q1
7 quarters
ANNX icon
32
Annexon
ANNX
$682M
$86.3M 1.05%
3,448,030
+5,908
+0.2% +$152K
2020 Q3
1 quarter
ALXO icon
33
ALX Oncology
ALXO
$138M
$82.8M 1%
960,400
+553,000
+136% +$33.3M
2020 Q3
1 quarter
CI icon
34
Cigna
CI
$79B
$79.8M 0.97%
383,093
-13,600
-3% -$2.67M
2019 Q4
4 quarters
UNH icon
35
UnitedHealth
UNH
$365B
$78.8M 0.95%
+224,639
New +$75.3M
2020 Q4
0 quarters
ELV icon
36
Elevance Health
ELV
$92.9B
$78.5M 0.95%
+244,332
New +$75M
2020 Q4
0 quarters
PLRX icon
37
Pliant Therapeutics
PLRX
$60.2M
$77M 0.93%
3,388,376
-3,381
-0.1% -$84.8K
2020 Q2
2 quarters
NVRO icon
38
DELISTED
NEVRO CORP.
NVRO
$76.8M 0.93%
443,909
-15,700
-3% -$2.54M
2019 Q1
7 quarters
IMGN icon
39
DELISTED
Immunogen Inc
IMGN
$67.9M 0.82%
10,528,179
+50,300
+0.5% +$293K
2017 Q1
15 quarters
GNMK
40
DELISTED
GenMark Diagnostics, Inc
GNMK
$66.2M 0.8%
4,537,400
-176,200
-4% -$2.34M
2020 Q2
2 quarters
AKRO icon
41
DELISTED
Akero Therapeutics
AKRO
$59.9M 0.73%
2,322,557
-13,800
-0.6% -$384K
2019 Q2
6 quarters
EIDX
42
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$59.5M 0.72%
452,295
-13,910
-3% -$1.23M
2018 Q2
10 quarters
NGNE icon
43
Neurogene
NGNE
$479M
$58.3M 0.71%
206,593
-2,041
-1% -$499K
2019 Q4
4 quarters
BIIB icon
44
Biogen
BIIB
$34.8B
$53M 0.64%
216,247
-111,200
-34% -$28.7M
2019 Q4
4 quarters
ICUI icon
45
ICU Medical
ICUI
$4.18B
$51.8M 0.63%
241,454
+83,400
+53% +$16.2M
2020 Q2
2 quarters
ZYME icon
46
Zymeworks
ZYME
$1.85B
$51.4M 0.62%
1,088,300
-13,300
-1% -$618K
2020 Q1
3 quarters
CLDX icon
47
Celldex Therapeutics
CLDX
$2.27B
$47.5M 0.58%
2,711,616
+722,416
+36% +$13M
2020 Q2
2 quarters
BNTX icon
48
BioNTech
BNTX
$22.7B
$47.3M 0.57%
580,746
-654,899
-53% -$64.3M
2019 Q4
4 quarters
UBER icon
49
Uber
UBER
$146B
$42.5M 0.51%
+833,845
New +$37.4M
2020 Q4
0 quarters
BCEL
50
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$40M 0.48%
2,476,068
-72,100
-3% -$1.08M
2019 Q2
6 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2020 Portfolio in Review

As of Q4 2020, Redmile Group held 97 positions worth $8.26B, up 52% from $5.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group deployed $660M of net new capital in Q4 2020, opening 16 new positions and adding to 23 existing holdings. Its largest new stake was Shattuck Labs: 5,619,914 shares worth $295M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was BioNTech, an estimated $64.3M trimmed.

  • Redmile Group's largest Q4 2020 buy was Shattuck Labs: 5,619,914 shares worth $295M.
  • Redmile Group added most to Invitae Corporation in Q4 2020, an estimated $242M increase.
  • Redmile Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $64.3M.
  • Redmile Group fully exited Immunomedics Inc in Q4 2020, selling an estimated $275M.
  • Redmile Group's ten largest holdings make up 47% of its $8.26B portfolio in Q4 2020.
  • Redmile Group opened 16 new positions and closed 10 in Q4 2020.
  • Redmile Group's portfolio value rose 52% quarter-over-quarter to $8.26B.

Based on Redmile Group's 13F filing for Q4 2020, filed 16 Feb 2021.